Publications by authors named "Isabelle L Meng"

Claim this Profile
P
Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial.
Riccardo Cappato, Michael D Ezekowitz, Stefan H Hohnloser, Isabelle Ling Meng, Melanie Wosnitza

Europace· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial.
Paulus Kirchhof, Michael D Ezekowitz, Yanish Purmah, Sonja Schiffer, Isabelle L Meng

TH Open· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).
Kazuo Miyazawa, Daniele Pastori, Christoph Hammerstingl, Riccardo Cappato, Isabelle Ling Meng

Ann Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
Gregory Y H Lip, Christoph Hammerstingl, Francisco Marin, Riccardo Cappato, Isabelle Ling Meng

Am Heart J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Stefan H Hohnloser, Riccardo Cappato, Michael D Ezekowitz, Thomas Evers, Kurtulus Sahin, Isabelle Ling Meng

Europace· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
Gregory Y H Lip, Christoph Hammerstingl, Francisco Marin, Riccardo Cappato, Isabelle Ling Meng

Am Heart J· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Riccardo Cappato, Michael D Ezekowitz, Allan L Klein, A John Camm, Chang-Sheng Ma, Isabelle Ling Meng

Eur Heart J· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Michael D Ezekowitz, Riccardo Cappato, Allan L Klein, A John Camm, Chang-Sheng Ma, Isabelle Ling Meng

Am Heart J· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
Yuqi Wang, Chen Wang, Zhong Chen, Jiwei Zhang, Zhihong Liu, Isabelle Ling Meng

Thromb J· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis